CORTROSYN™ (cosyntropin) for Injection exhibits slight immunologic activity, does not contain animal protein and is therefore less risky to use than natural ACTH. Patients known to be sensitized to natural ACTH with markedly positive skin tests will, with few exceptions, react negatively when tested intradermally with CORTROSYN™. Most patients with a history of a previous hypersensitivity reaction to natural ACTH or a pre-existing allergic disease will tolerate CORTROSYN™. Despite this however, CORTROSYN™ is not completely devoid of immunologic activity and hypersensitivity reactions including rare anaphylaxis are possible. Therefore, the physician should be prepared, prior to injection, to treat any possible acute hypersensitivity reaction.
Oral intake of cissus quadrangularis (petroleum ether extract of the stem; % yield) in a rat model mimicking menopause (ovarectomized rats) at a dose of 500mg/kg for ninety days is able to fully prevent losses of bone strength and prevent up to 86% of the losses in bone thickness;  cissus quadrangularis showed comparable efficacy to /kg of the SERM known as raloxifene, and while this study is duplciated in Medline  the design has been replicated where a month of cissus quadrangularis supplementation (500mg/kg petroleum ether extract) was comparable in efficacy 25mg/kg raloxifene in ovarectomized rats.